Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
23 hedge funds and large institutions have $10.5M invested in Astria Therapeutics in 2018 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 1 increasing their positions, 6 reducing their positions, and 12 closing their positions.
0.02% more ownership
Funds ownership: 0.54% → 0.56% (+0.02%)
18% less funds holding
Funds holding: 28 → 23 (-5)
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
43% less capital invested
Capital invested by funds: $18.4M → $10.5M (-$7.93M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
83% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Blackstone Inc
New York
|
+$1.27M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$406K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$213K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$72.3K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$19.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$1.1M |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$584K |
| 3 |
BlackRock
New York
|
-$136K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$72K |
| 5 |
Millennium Management
New York
|
-$66K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BFO
26
Boston Family Office
Boston,
Massachusetts
| – | -$20K | -408 | Closed |
|
27
Russell Investments Group
London,
United Kingdom
| – | -$19K | -390 | Closed |
|
|
BFM
28
Boothbay Fund Management
New York
| – | -$18K | -380 | Closed |
|
29
State Street
Boston,
Massachusetts
| – | -$14K | -302 | Closed |
|
30
Invesco
Atlanta,
Georgia
| – | -$13K | -276 | Closed |
|
31
Commonwealth Equity Services
Waltham,
Massachusetts
| – | -$9K | -199 | Closed |
|
32
LPL Financial
San Diego,
California
| – | -$8K | -167 | Closed |
|
33
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$38 | -1 | -6% |
|
|
TRCT
34
Tower Research Capital (TRC)
New York
| – | +$644 | +17 | New |
|
ATXS Hedge Fund Activity: Q4 2018 in Review
23 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q4 2018, worth a combined $10.5M — down 43% from $18.4M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of ATXS and 8 opened new positions — a net loss of 4 holders — while 6 trimmed existing stakes and 1 added.
The largest buyer was Blackstone Inc, opening a new position worth an estimated $1.27M. The largest seller was Stonepine Capital Management, cutting an estimated $1.1M.
- 23 institutional investors held Astria Therapeutics (ATXS) as of Q4 2018, down from 28 in Q3 2018.
- Funds reported $10.5M of Astria Therapeutics stock for Q4 2018, down 43% quarter-over-quarter.
- 8 funds opened new Astria Therapeutics positions in Q4 2018 and 12 closed out, a net change of -4 holders.
- The largest Astria Therapeutics buyer in Q4 2018 was Blackstone Inc, an estimated $1.27M added.
- The largest Astria Therapeutics seller in Q4 2018 was Stonepine Capital Management, an estimated $1.1M sold.
Based on aggregated 13F filings for Q4 2018.